Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $202.29 Average PT from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $202.29.

A number of equities research analysts have recently weighed in on KRYS shares. Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech during the third quarter valued at $40,000. Teachers Retirement System of The State of Kentucky raised its stake in Krystal Biotech by 198.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock valued at $1,640,000 after buying an additional 5,989 shares during the last quarter. Geode Capital Management LLC raised its stake in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares during the last quarter. Finally, Main Management ETF Advisors LLC purchased a new position in Krystal Biotech during the third quarter valued at $706,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

KRYS opened at $184.40 on Friday. The stock’s 50 day simple moving average is $181.31 and its 200 day simple moving average is $184.78. Krystal Biotech has a 1 year low of $103.83 and a 1 year high of $219.34. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of 104.18 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period last year, the company earned ($0.67) EPS. As a group, sell-side analysts anticipate that Krystal Biotech will post 2.97 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).